CoChat
Sign Up
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment

Anitha, A., Deepa, N., Chennazhi, K.P., Lakshmanan, Vinoth-Kumar, Jayakumar, R.·2014·Biochimica et Biophysica Acta (BBA) - General Subjects
DOI 10.1016/j.bbagen.2014.06.004
Open this paper in CoChat — free account

Abstract

Background Evaluation of the combinatorial anticancer effects of curcumin/5-fluorouracil loaded thiolated chitosan nanoparticles (CRC-TCS-NPs/5-FU-TCS-NPs) on colon cancer cells and the analysis of pharmacokinetics and biodistribution of CRC-TCS-NPs/5-FU-TCS-NPs in a mouse model. Methods CRC-TCS-NPs/5-FU-TCS-NPs were developed by ionic cross-linking. The in vitro combinatorial anticancer effect of the nanomedicine was proven by different assays. Further the pharmacokinetics and biodistribution analyses were performed in Swiss Albino mouse using HPLC. Results The 5-FU-TCS-NPs (size: 150±40nm, zeta potential: +48.2±5mV) and CRC-TCS-NPs (size: 150±20nm, zeta potential: +35.7±3mV) were proven to be compatible with blood. The in vitro drug release studies at pH4.5 and 7.4 showed a sustained release profile over a period of 4 days, where both the systems exhibited a higher release in acidic pH. The in vitro combinatorial anticancer effects in colon cancer (HT29) cells using MTT, live/dead, mitochondrial membrane potential and cell cycle analysis measurements confirmed the enhanced anticancer effects (2.5 to 3 fold). The pharmacokinetic studies confirmed the improved plasma concentrations of 5-FU and CRC up to 72h, unlike bare CRC and 5-FU. Conclusions To conclude, the combination of 5-FU-TCS-NPs and CRC-TCS-NPs showed enhanced anticancer effects on colon cancer cells in vitro and improved the bioavailability of the drugs in vivo. General significance The enhanced anticancer effects…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbagen.2014.06.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 69

  1. Pisani, 1993, Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden, Int. J. Cancer, 55, 891, 10.1002/ijc.2910550604 · DOI
  2. Sakamoto, 2010, Targeting NF-κB for colorectal cancer, Expert Opin. Ther. Targets, 14, 593, 10.1517/14728221003769903 · DOI
  3. Li, 2008, Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles, BMC Cancer, 15, 103, 10.1186/1471-2407-8-103 · DOI
  4. Ortiz, 2012, 5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer, Int. J. Nanomedicine, 7, 95
  5. Yan, 2010, In vivo biodistribution for tumor targeting of 5-fluorouracil loaded N-succinyl chitosan nanoparticles, Pharm. Soc. Jpn., 130, 801, 10.1248/yakushi.130.801 · DOI
  6. Zhang, 2011, Folate-functionalized nanoparticles for controlled 5-fluorouracil delivery, J. Colloid Interface Sci., 354, 202, 10.1016/j.jcis.2010.10.054 · DOI
  7. de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J. Clin. Oncol., 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
  8. Diasio, 2000, The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil, Pharmacology, 61, 199, 10.1159/000028401 · DOI
  9. Viguier, 2005, ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer, Clin. Cancer Res., 11, 6212, 10.1158/1078-0432.CCR-04-2216 · DOI
  10. Guo, 2006, Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil, Acta Pharmacol. Sin., 27, 1375, 10.1111/j.1745-7254.2006.00421.x · DOI
  11. Hwang, 2005, Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways, Biochem. Biophys. Res. Commun., 332, 433, 10.1016/j.bbrc.2005.04.143 · DOI
  12. Carnesecchi, 2004, Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts, Cancer Lett., 215, 53, 10.1016/j.canlet.2004.06.019 · DOI
  13. Du, 2006, Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29, Chemotherapy, 52, 23, 10.1159/000090238 · DOI
  14. Srimuangwong, 2012, Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats, World J. Gastroenterol., 18, 6951, 10.3748/wjg.v18.i47.6951 · DOI
  15. Sun, 2008, Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells, Mol. Cancer Ther., 7, 464, 10.1158/1535-7163.MCT-07-2272 · DOI
  16. Dhillon, 2008, Phase II trial of curcumin in patients with advanced pancreatic cancer, Clin. Cancer Res., 14, 4491, 10.1158/1078-0432.CCR-08-0024 · DOI
  17. Nakamura, 2002, Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines, Int. J. Oncol., 21, 825
  18. Wu, 2010, Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways, Anticancer Res., 30, 2125
  19. Jeremy, 2007, Curcumin for chemoprevention of colon cancer, Cancer Lett., 255, 170, 10.1016/j.canlet.2007.03.005 · DOI
  20. Su, 2006, Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3, Anticancer Res., 26, 4379
  21. Hanif, 1997, Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway, J. Lab. Clin. Med., 130, 576, 10.1016/S0022-2143(97)90107-4 · DOI
  22. Ireson, 2002, Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine, Cancer Epidemiol. Biomarkers Prev., 11, 105
  23. Shaikh, 2009, Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer, Eur. J. Pharm. Sci., 37, 223, 10.1016/j.ejps.2009.02.019 · DOI
  24. Kakkar, 2011, Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin, Mol. Nutr. Food Res., 55, 495, 10.1002/mnfr.201000310 · DOI
  25. Acharya, 2011, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect, Adv. Drug Deliv. Rev., 63, 170, 10.1016/j.addr.2010.10.008 · DOI
  26. Tsai, 2011, Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration, Int. J. Pharm., 416, 331, 10.1016/j.ijpharm.2011.06.030 · DOI
  27. Yallapu, 2012, Curcumin nanoformulations: a future nanomedicine for cancer, Drug Discov. Today, 17, 71, 10.1016/j.drudis.2011.09.009 · DOI
  28. Srimuangwong, 2012, Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells, World J. Gastroenterol., 18, 2383, 10.3748/wjg.v18.i19.2383 · DOI
  29. Bernkop-Schnurch, 2003, Thiolated polymers–thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates, Int. J. Pharm., 260, 229, 10.1016/S0378-5173(03)00271-0 · DOI
  30. Anitha, 2011, Development of mucoadhesive thiolated chitosan nanoparticles for biomedical applications, Carbohydr. Polym., 83, 66, 10.1016/j.carbpol.2010.07.028 · DOI
  31. Anitha, 2012, Curcumin-loaded N,O-carboxymethyl chitosan nanoparticles for cancer drug delivery, J. Biomater. Sci. Polym. Ed., 23, 1381, 10.1163/092050611X581534 · DOI
  32. Kubista, 2006, Anticancer effects of zoledronic acid against human osteosarcoma cells, J. Orthop. Res., 24, 1145, 10.1002/jor.20129 · DOI
  33. Choi, 2010, Biocompatible nanoparticles intercalated with anticancer drug for target delivery: pharmacokinetic and biodistribution study, J. Nanosci. Nanotechnol., 10, 2913, 10.1166/jnn.2010.1415 · DOI
  34. Anand, 2010, Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo, Biochem. Pharmacol., 79, 330, 10.1016/j.bcp.2009.09.003 · DOI
  35. Ma, 2007, High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin, Biomed. Chromatogr., 21, 546, 10.1002/bmc.795 · DOI
  36. Song, 2011, Curcumin-loaded PLGA–PEG–PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo, J. Colloid Interface Sci., 354, 116, 10.1016/j.jcis.2010.10.024 · DOI
  37. Shabir, 2003, J. Chromatogr. A, 987, 57, 10.1016/S0021-9673(02)01536-4 · DOI
  38. Smitha, 2013, In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery, Colloids Surf. B, 104, 245, 10.1016/j.colsurfb.2012.11.031 · DOI
  39. Manjunath, 2005, Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration, J. Control. Release, 107, 215, 10.1016/j.jconrel.2005.06.006 · DOI
  40. Alexiou, 2001, Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting, J. Magn. Magn. Mater., 225, 187, 10.1016/S0304-8853(00)01256-7 · DOI
  41. Huang, 2010, Synthesis and characterization of bovine serum albumin-conjugated copper sulfide nanocomposites, 10.1155/2010/641545 · DOI
  42. Anitha, 2009, Synthesis, characterization, cytotoxicity and antibacterial studies of chitosan, O-carboxymethyl and N,O-carboxymethyl chitosan nanoparticles, Carbohydr. Polym., 78, 672, 10.1016/j.carbpol.2009.05.028 · DOI
  43. Devika, 2006, Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: a technical note, AAPS Pharm. Sci. Technol., 7, 1
  44. Rejinold, 2011, Saponin-loaded chitosan nanoparticles and their cytotoxicity to cancer cell lines in vitro, Carbohydr. Polym., 84, 407, 10.1016/j.carbpol.2010.11.056 · DOI
  45. Yassin, 2010, Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer, Int. J. Med. Sci., 7, 398, 10.7150/ijms.7.398 · DOI
  46. Rejinold, 2011, Biodegradable and thermo-sensitive chitosan-g-poly (N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier, Carbohydr. Polym., 83, 776, 10.1016/j.carbpol.2010.08.052 · DOI
  47. Yan, 2006, Nanoparticles of 5-fluorouracil (5-FU) loaded N-succinyl–chitosan (Suc–Chi) for cancer chemotherapy: preparation, characterization — in vitro drug release and antitumour activity, J. Pharm. Pharmacol., 58, 1177, 10.1211/jpp.58.9.0003 · DOI
  48. Bisht, 2007, Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy, J. Nanobiotechnol., 5, 3, 10.1186/1477-3155-5-3 · DOI
  49. Yallapu, 2010, beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells, Colloids Surf. B, 79, 113, 10.1016/j.colsurfb.2010.03.039 · DOI
  50. Kean, 2010, Biodegradation, biodistribution and toxicity of chitosan, Adv. Drug Deliv. Rev., 62, 3, 10.1016/j.addr.2009.09.004 · DOI · Paper page
  51. Agnihotri, 2004, Recent advances on chitosan-based micro- and nanoparticles in drug delivery, J. Control. Release, 100, 5, 10.1016/j.jconrel.2004.08.010 · DOI
  52. Aranaz, 2009, Functional characterization of chitin and chitosan, Curr. Chem. Biol., 3, 203
  53. Gutierrez, 2012, Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles, Nanomed. Nanotechnol. Biol. Med., 8, 328, 10.1016/j.nano.2011.06.014 · DOI
  54. Koziara, 2005, Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles, Pharm. Res., 22, 1821, 10.1007/s11095-005-7547-7 · DOI
  55. Yu, 2012, Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles, Inorg. Chem., 51, 8956, 10.1021/ic301050v · DOI
  56. Agarwal, 1998, The p53 network, J. Biol. Chem., 273, 1, 10.1074/jbc.273.1.1 · DOI
  57. Cheng, 2014, Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics, Int. J. Nanomedicine, 24, 695
  58. Cheng, 2012, Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects, World J. Gastroenterol., 18, 6076, 10.3748/wjg.v18.i42.6076 · DOI
  59. Khalil, 2013, Pharmacokinetics of curcumin-loaded PLGA and PLGA–PEG blend nanoparticles after oral administration in rats, Colloids Surf. B, 101, 353, 10.1016/j.colsurfb.2012.06.024 · DOI
  60. Feng, 2012, Preparation and in vivo pharmacokinetics of curcumin-loaded PCL–PEG–PCL triblock copolymeric nanoparticles, Int. J. Nanomedicine, 7, 4089, 10.2147/IJN.S33607 · DOI
  61. Zhongfa, 2012, Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice, Cancer Chemother. Pharmacol., 69, 679, 10.1007/s00280-011-1749-y · DOI
  62. Jiabei, 2013, Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability, Colloids Surf. B, 111, 367, 10.1016/j.colsurfb.2013.06.032 · DOI
  63. Ghahremankhani, 2008, PLGA–PEG–PLGA tri-block co-polymers as in situ gel-forming peptide delivery system: effect of formulation properties on peptide release, Pharm. Dev. Technol., 13, 49, 10.1080/10837450701702842 · DOI
  64. Thomas, 2011, Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy, J. Control. Release, 150, 212, 10.1016/j.jconrel.2010.11.018 · DOI
  65. Schmidt, 2010, Significance of protein binding in pharmacokinetics and pharmacodynamics, J. Pharm. Sci., 99, 1107, 10.1002/jps.21916 · DOI
  66. Ho, 1986, Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate, Anticancer Res., 6, 781
  67. Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283, 10.1016/S0031-6997(24)01494-7 · DOI
  68. Park, 1995, Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition, Biomaterials, 16, 1123, 10.1016/0142-9612(95)93575-X · DOI · Paper page
  69. King, 2001, Hepatotoxicity of chemotherapy, Oncologist, 6, 162, 10.1634/theoncologist.6-2-162 · DOI

Cited by

Sorted by citations

See all 158

Metadata

Authors
Anitha, A., Deepa, N., Chennazhi, K. P., Lakshmanan, V.-K., & Jayakumar, R.
Venue
Biochimica et Biophysica Acta (BBA) - General Subjects
Publisher
Elsevier BV
Published
2014-09
Volume
1840
Issue
9
Pages
2730-2743
ISSN
0304-4165
DOI
10.1016/j.bbagen.2014.06.004
Cited by
158
References
1
Language
en
Update notices
erratum (2019-05-01)
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. https://app.cochat.ai/papers/10.1016/j.bbagen.2014.06.004
The paper
Anitha, A., Deepa, N., Chennazhi, K. P., Lakshmanan, V.-K., & Jayakumar, R. (2014). Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. Biochimica et Biophysica Acta (BBA) - General Subjects. https://doi.org/10.1016/j.bbagen.2014.06.004